SEC Form 4 · accession 0001179110-18-001609
ENDOCYTE INC · ECYT
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Christopher P Leamon
Officer — Vice President of Research
Period of report
Feb 2, 2018
Accepted (ET)
Feb 6, 2018 · 12:03 pm EST
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001235007
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common StockF1,F2 | Feb 2, 2018 | F | 1,487 | $3.12 | D | 128,380 | D | |
| Common StockF3 | Feb 4, 2018 | F | 1,736 | $3.12 | D | 126,644 | D |
Table II — derivative securities
No Table II lines on this filing.
Explanation of responses
- F1Represents shares withheld to satisfy tax withholding obligations associated with the settlement of 4,375 restricted stock units in the form of Company common stock on a one-for-one basis on February 2, 2018.
- F2Includes 2,519 shares acquired under the Endocyte, Inc. 2010 Employee Stock Purchase Plan on December 15, 2017.
- F3Represents shares withheld to satisfy tax withholding obligations associated with the settlement of 2,917 and 2,188 restricted stock units in the form of Company common stock on a one-for-one basis on February 4, 2018.